Glioblastoma Multiforme Treatment MarketGlioblastoma Multiforme Treatment Market Analysis By Treatment (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Other Treatments), By Drug Class (Temozolomide, Lomustine, Bevacizumab, Other Drug Classes), By End-use (Hospitals, Clinics, Ambulatory Surgical Centers), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Published date: Oct 2024
Report ID: 49807
Number of Pages: 372
Format:

Fact Checked

Cite this Research

- 1. Executive Summary
  - 1.1. Definition
  - 1.2. Taxonomy
  - 1.3. Research Scope
  - 1.4. Key Analysis
  - 1.5. Key Findings by Major Segments
  - 1.6. Top strategies by Major Players
- 2. Global Glioblastoma Multiforme Treatment Overview
  - 2.1. Glioblastoma Multiforme Treatment Dynamics
    
    2.1.1. Drivers
    
    2.1.2. Opportunities
    
    2.1.3. Restraints
    
    2.1.4. Challenges
  - 2.2. Macro-economic Factors
  - 2.3. Regulatory Framework
  - 2.4. Market Investment Feasibility Index
  - 2.5. PEST Analysis
  - 2.6. PORTER’S Five Force Analysis
  - 2.7. Drivers & Restraints Impact Analysis
  - 2.8. Industry Chain Analysis
  - 2.9. Cost Structure Analysis
  - 2.10. Marketing Strategy
  - 2.11. Russia-Ukraine War Impact Analysis
  - 2.12. Opportunity Map Analysis
  - 2.13. Market Competition Scenario Analysis
  - 2.14. Product Life Cycle Analysis
  - 2.15. Opportunity Orbits
  - 2.16. Manufacturer Intensity Map
  - 2.17. Major Companies sales by Value & Volume
- 3. Global Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, 2016-2032
  - 3.1. Global Glioblastoma Multiforme Treatment Analysis, 2016-2021
  - 3.2. Global Glioblastoma Multiforme Treatment Opportunity and Forecast, 2023-2032
  - 3.3. Global Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By Treatment, 2016-2032
    
    3.3.1. Global Glioblastoma Multiforme Treatment Analysis by Treatment: Introduction
    
    3.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Treatment, 2016-2032
    
    3.3.3. Surgery
    
    3.3.3.1. Surgery1
    
    3.3.3.2. Surgery2
    
    3.3.4. Targeted Therapy
    
    3.3.5. Radiation Therapy
    
    3.3.6. Chemotherapy
    
    3.3.7. Tumor Treating Field (TTF) Therapy
    
    3.3.8. Immunotherapy
  - 3.4. Global Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
    
    3.4.1. Global Glioblastoma Multiforme Treatment Analysis by Drug Class: Introduction
    
    3.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
    
    3.4.3. Temozolomide
    
    3.4.4. Lomustine
    
    3.4.5. Bevacizumab
    
    3.4.6. Carmustine Wafers
    
    3.4.7. Other Drug Classes
  - 3.5. Global Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By End-use, 2016-2032
    
    3.5.1. Global Glioblastoma Multiforme Treatment Analysis by End-use: Introduction
    
    3.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-use, 2016-2032
    
    3.5.3. Hospitals
    
    3.5.4. Clinics
    
    3.5.5. Ambulatory Surgical Centers
- 4. North America Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, 2016-2032
  - 4.1. North America Glioblastoma Multiforme Treatment Analysis, 2016-2021
  - 4.2. North America Glioblastoma Multiforme Treatment Opportunity and Forecast, 2023-2032
  - 4.3. North America Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By Treatment, 2016-2032
    
    4.3.1. North America Glioblastoma Multiforme Treatment Analysis by Treatment: Introduction
    
    4.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Treatment, 2016-2032
    
    4.3.3. Surgery
    
    4.3.3.1. Surgery1
    
    4.3.3.2. Surgery2
    
    4.3.4. Targeted Therapy
    
    4.3.5. Radiation Therapy
    
    4.3.6. Chemotherapy
    
    4.3.7. Tumor Treating Field (TTF) Therapy
    
    4.3.8. Immunotherapy
  - 4.4. North America Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
    
    4.4.1. North America Glioblastoma Multiforme Treatment Analysis by Drug Class: Introduction
    
    4.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
    
    4.4.3. Temozolomide
    
    4.4.4. Lomustine
    
    4.4.5. Bevacizumab
    
    4.4.6. Carmustine Wafers
    
    4.4.7. Other Drug Classes
  - 4.5. North America Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By End-use, 2016-2032
    
    4.5.1. North America Glioblastoma Multiforme Treatment Analysis by End-use: Introduction
    
    4.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-use, 2016-2032
    
    4.5.3. Hospitals
    
    4.5.4. Clinics
    
    4.5.5. Ambulatory Surgical Centers
  - 4.6. North America Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
    
    4.6.1. North America Glioblastoma Multiforme Treatment Analysis by Country : Introduction
    
    4.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    
    4.6.2.1. U.S.
    
    4.6.2.2. Canada
    
    4.6.2.3. Mexico
- 5. Europe Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, 2016-2032
  - 5.1. Europe Glioblastoma Multiforme Treatment Analysis, 2016-2021
  - 5.2. Europe Glioblastoma Multiforme Treatment Opportunity and Forecast, 2023-2032
  - 5.3. Europe Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By Treatment, 2016-2032
    
    5.3.1. Europe Glioblastoma Multiforme Treatment Analysis by Treatment: Introduction
    
    5.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Treatment, 2016-2032
    
    5.3.3. Surgery
    
    5.3.3.1. Surgery1
    
    5.3.3.2. Surgery2
    
    5.3.4. Targeted Therapy
    
    5.3.5. Radiation Therapy
    
    5.3.6. Chemotherapy
    
    5.3.7. Tumor Treating Field (TTF) Therapy
    
    5.3.8. Immunotherapy
  - 5.4. Europe Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
    
    5.4.1. Europe Glioblastoma Multiforme Treatment Analysis by Drug Class: Introduction
    
    5.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
    
    5.4.3. Temozolomide
    
    5.4.4. Lomustine
    
    5.4.5. Bevacizumab
    
    5.4.6. Carmustine Wafers
    
    5.4.7. Other Drug Classes
  - 5.5. Europe Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By End-use, 2016-2032
    
    5.5.1. Europe Glioblastoma Multiforme Treatment Analysis by End-use: Introduction
    
    5.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-use, 2016-2032
    
    5.5.3. Hospitals
    
    5.5.4. Clinics
    
    5.5.5. Ambulatory Surgical Centers
  - 5.6. Europe Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
    
    5.6.1. Europe Glioblastoma Multiforme Treatment Analysis by Country : Introduction
    
    5.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    
    5.6.2.1. U.K.
    
    5.6.2.2. Germany
    
    5.6.2.3. France
    
    5.6.2.4. Spain
    
    5.6.2.5. Italy
    
    5.6.2.6. Russia
    
    5.6.2.7. Rest of Europe
- 6. Asia-Pacific Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, 2016-2032
  - 6.1. Asia-Pacific Glioblastoma Multiforme Treatment Analysis, 2016-2021
  - 6.2. Asia-Pacific Glioblastoma Multiforme Treatment Opportunity and Forecast, 2023-2032
  - 6.3. Asia-Pacific Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By Treatment, 2016-2032
    
    6.3.1. Asia-Pacific Glioblastoma Multiforme Treatment Analysis by Treatment: Introduction
    
    6.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Treatment, 2016-2032
    
    6.3.3. Surgery
    
    6.3.3.1. Surgery1
    
    6.3.3.2. Surgery2
    
    6.3.4. Targeted Therapy
    
    6.3.5. Radiation Therapy
    
    6.3.6. Chemotherapy
    
    6.3.7. Tumor Treating Field (TTF) Therapy
    
    6.3.8. Immunotherapy
  - 6.4. Asia-Pacific Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
    
    6.4.1. Asia-Pacific Glioblastoma Multiforme Treatment Analysis by Drug Class: Introduction
    
    6.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
    
    6.4.3. Temozolomide
    
    6.4.4. Lomustine
    
    6.4.5. Bevacizumab
    
    6.4.6. Carmustine Wafers
    
    6.4.7. Other Drug Classes
  - 6.5. Asia-Pacific Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By End-use, 2016-2032
    
    6.5.1. Asia-Pacific Glioblastoma Multiforme Treatment Analysis by End-use: Introduction
    
    6.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-use, 2016-2032
    
    6.5.3. Hospitals
    
    6.5.4. Clinics
    
    6.5.5. Ambulatory Surgical Centers
  - 6.6. Asia-Pacific Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
    
    6.6.1. Asia-Pacific Glioblastoma Multiforme Treatment Analysis by Country : Introduction
    
    6.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    
    6.6.2.1. China
    
    6.6.2.2. Japan
    
    6.6.2.3. South Korea
    
    6.6.2.4. India
    
    6.6.2.5. Rest of Asia-Pacific
- 7. South America Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, 2016-2032
  - 7.1. South America Glioblastoma Multiforme Treatment Analysis, 2016-2021
  - 7.2. South America Glioblastoma Multiforme Treatment Opportunity and Forecast, 2023-2032
  - 7.3. South America Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By Treatment, 2016-2032
    
    7.3.1. South America Glioblastoma Multiforme Treatment Analysis by Treatment: Introduction
    
    7.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Treatment, 2016-2032
    
    7.3.3. Surgery
    
    7.3.3.1. Surgery1
    
    7.3.3.2. Surgery2
    
    7.3.4. Targeted Therapy
    
    7.3.5. Radiation Therapy
    
    7.3.6. Chemotherapy
    
    7.3.7. Tumor Treating Field (TTF) Therapy
    
    7.3.8. Immunotherapy
  - 7.4. South America Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
    
    7.4.1. South America Glioblastoma Multiforme Treatment Analysis by Drug Class: Introduction
    
    7.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
    
    7.4.3. Temozolomide
    
    7.4.4. Lomustine
    
    7.4.5. Bevacizumab
    
    7.4.6. Carmustine Wafers
    
    7.4.7. Other Drug Classes
  - 7.5. South America Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By End-use, 2016-2032
    
    7.5.1. South America Glioblastoma Multiforme Treatment Analysis by End-use: Introduction
    
    7.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-use, 2016-2032
    
    7.5.3. Hospitals
    
    7.5.4. Clinics
    
    7.5.5. Ambulatory Surgical Centers
  - 7.6. South America Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
    
    7.6.1. South America Glioblastoma Multiforme Treatment Analysis by Country : Introduction
    
    7.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    
    7.6.2.1. Brazil
    
    7.6.2.2. Argentina
    
    7.6.2.3. Rest of South America
- 8. Middle East and Africa Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, 2016-2032
  - 8.1. Middle East and Africa Glioblastoma Multiforme Treatment Analysis, 2016-2021
  - 8.2. Middle East and Africa Glioblastoma Multiforme Treatment Opportunity and Forecast, 2023-2032
  - 8.3. Middle East and Africa Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By Treatment, 2016-2032
    
    8.3.1. Middle East and Africa Glioblastoma Multiforme Treatment Analysis by Treatment: Introduction
    
    8.3.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Treatment, 2016-2032
    
    8.3.3. Surgery
    
    8.3.3.1. Surgery1
    
    8.3.3.2. Surgery2
    
    8.3.4. Targeted Therapy
    
    8.3.5. Radiation Therapy
    
    8.3.6. Chemotherapy
    
    8.3.7. Tumor Treating Field (TTF) Therapy
    
    8.3.8. Immunotherapy
  - 8.4. Middle East and Africa Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By Drug Class, 2016-2032
    
    8.4.1. Middle East and Africa Glioblastoma Multiforme Treatment Analysis by Drug Class: Introduction
    
    8.4.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Drug Class, 2016-2032
    
    8.4.3. Temozolomide
    
    8.4.4. Lomustine
    
    8.4.5. Bevacizumab
    
    8.4.6. Carmustine Wafers
    
    8.4.7. Other Drug Classes
  - 8.5. Middle East and Africa Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By End-use, 2016-2032
    
    8.5.1. Middle East and Africa Glioblastoma Multiforme Treatment Analysis by End-use: Introduction
    
    8.5.2. Market Size Absolute $ Opportunity Analysis and Forecast, By End-use, 2016-2032
    
    8.5.3. Hospitals
    
    8.5.4. Clinics
    
    8.5.5. Ambulatory Surgical Centers
  - 8.6. Middle East and Africa Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By Country , 2016-2032
    
    8.6.1. Middle East and Africa Glioblastoma Multiforme Treatment Analysis by Country : Introduction
    
    8.6.2. Market Size Absolute $ Opportunity Analysis and Forecast, Country , 2016-2032
    
    8.6.2.1. GCC
    
    8.6.2.2. Israel
    
    8.6.2.3. South Africa
    
    8.6.2.4. Rest of MEA
- 9. Global Glioblastoma Multiforme Treatment Analysis, Opportunity and Forecast, By Region , 2016-2032
  - 9.1. Global Glioblastoma Multiforme Treatment Analysis by Region : Introduction
  - 9.2. Market Size Absolute $ Opportunity Analysis and Forecast, By Region , 2016-2032
    
    9.2.1. North America
    
    9.2.2. Europe
    
    9.2.3. Asia-Pacific
    
    9.2.4. South America
    
    9.2.5. Middle East and Africa
- 10. Global Glioblastoma Multiforme Treatment Competitive Landscape, Market Share Analysis, and Company Profiles
  - 10.1. Market Share Analysis
  - 10.2. Company Profiles
  - 10.3. Merck & Co., Inc.
    
    10.3.1. Company Overview
    
    10.3.2. Financial Highlights
    
    10.3.3. Product Portfolio
    
    10.3.4. SWOT Analysis
    
    10.3.5. Key Strategies and Developments
  - 10.4. Teva Pharmaceutical Industries Ltd.
    
    10.4.1. Company Overview
    
    10.4.2. Financial Highlights
    
    10.4.3. Product Portfolio
    
    10.4.4. SWOT Analysis
    
    10.4.5. Key Strategies and Developments
  - 10.5. Amgen, Inc.
    
    10.5.1. Company Overview
    
    10.5.2. Financial Highlights
    
    10.5.3. Product Portfolio
    
    10.5.4. SWOT Analysis
    
    10.5.5. Key Strategies and Developments
  - 10.6. Sun Pharmaceutical Industries Ltd.
    
    10.6.1. Company Overview
    
    10.6.2. Financial Highlights
    
    10.6.3. Product Portfolio
    
    10.6.4. SWOT Analysis
    
    10.6.5. Key Strategies and Developments
  - 10.7. F. Hoffmann-La Roche Ltd.
    
    10.7.1. Company Overview
    
    10.7.2. Financial Highlights
    
    10.7.3. Product Portfolio
    
    10.7.4. SWOT Analysis
    
    10.7.5. Key Strategies and Developments
  - 10.8. Pfizer Inc.
    
    10.8.1. Company Overview
    
    10.8.2. Financial Highlights
    
    10.8.3. Product Portfolio
    
    10.8.4. SWOT Analysis
    
    10.8.5. Key Strategies and Developments
  - 10.9. Amgen, Inc.
    
    10.9.1. Company Overview
    
    10.9.2. Financial Highlights
    
    10.9.3. Product Portfolio
    
    10.9.4. SWOT Analysis
    
    10.9.5. Key Strategies and Developments
  - 10.10. Arbor Pharmaceuticals, LLC
    
    10.10.1. Company Overview
    
    10.10.2. Financial Highlights
    
    10.10.3. Product Portfolio
    
    10.10.4. SWOT Analysis
    
    10.10.5. Key Strategies and Developments
  - 10.11. Amneal Pharmaceuticals
    
    10.11.1. Company Overview
    
    10.11.2. Financial Highlights
    
    10.11.3. Product Portfolio
    
    10.11.4. SWOT Analysis
    
    10.11.5. Key Strategies and Developments
  - 10.12. Other Key Players
    
    10.12.1. Company Overview
    
    10.12.2. Financial Highlights
    
    10.12.3. Product Portfolio
    
    10.12.4. SWOT Analysis
    
    10.12.5. Key Strategies and Developments
- 11. Assumptions and Acronyms
- 12. Research Methodology
- 13. Contact
- List of Figures
  - Figure 1: Global Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by Treatment in 2022
  - Figure 2: Global Glioblastoma Multiforme Treatment Market Attractiveness Analysis by Treatment, 2016-2032
  - Figure 3: Global Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by Drug Classin 2022
  - Figure 4: Global Glioblastoma Multiforme Treatment Market Attractiveness Analysis by Drug Class, 2016-2032
  - Figure 5: Global Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by End-usein 2022
  - Figure 6: Global Glioblastoma Multiforme Treatment Market Attractiveness Analysis by End-use, 2016-2032
  - Figure 7: Global Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by Region in 2022
  - Figure 8: Global Glioblastoma Multiforme Treatment Market Attractiveness Analysis by Region, 2016-2032
  - Figure 9: Global Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) (2016-2032)
  - Figure 10: Global Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Region (2016-2032)
  - Figure 11: Global Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Treatment (2016-2032)
  - Figure 12: Global Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Figure 13: Global Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
  - Figure 14: Global Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
  - Figure 15: Global Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Treatment (2016-2032)
  - Figure 16: Global Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Figure 17: Global Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
  - Figure 18: Global Glioblastoma Multiforme Treatment Market Share Comparison by Region (2016-2032)
  - Figure 19: Global Glioblastoma Multiforme Treatment Market Share Comparison by Treatment (2016-2032)
  - Figure 20: Global Glioblastoma Multiforme Treatment Market Share Comparison by Drug Class (2016-2032)
  - Figure 21: Global Glioblastoma Multiforme Treatment Market Share Comparison by End-use (2016-2032)
  - Figure 22: North America Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by Treatmentin 2022
  - Figure 23: North America Glioblastoma Multiforme Treatment Market Attractiveness Analysis by Treatment, 2016-2032
  - Figure 24: North America Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by Drug Classin 2022
  - Figure 25: North America Glioblastoma Multiforme Treatment Market Attractiveness Analysis by Drug Class, 2016-2032
  - Figure 26: North America Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by End-usein 2022
  - Figure 27: North America Glioblastoma Multiforme Treatment Market Attractiveness Analysis by End-use, 2016-2032
  - Figure 28: North America Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 29: North America Glioblastoma Multiforme Treatment Market Attractiveness Analysis by Country, 2016-2032
  - Figure 30: North America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) (2016-2032)
  - Figure 31: North America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 32: North America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Treatment (2016-2032)
  - Figure 33: North America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Figure 34: North America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
  - Figure 35: North America Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 36: North America Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Treatment (2016-2032)
  - Figure 37: North America Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Figure 38: North America Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
  - Figure 39: North America Glioblastoma Multiforme Treatment Market Share Comparison by Country (2016-2032)
  - Figure 40: North America Glioblastoma Multiforme Treatment Market Share Comparison by Treatment (2016-2032)
  - Figure 41: North America Glioblastoma Multiforme Treatment Market Share Comparison by Drug Class (2016-2032)
  - Figure 42: North America Glioblastoma Multiforme Treatment Market Share Comparison by End-use (2016-2032)
  - Figure 43: Europe Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by Treatmentin 2022
  - Figure 44: Europe Glioblastoma Multiforme Treatment Market Attractiveness Analysis by Treatment, 2016-2032
  - Figure 45: Europe Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by Drug Classin 2022
  - Figure 46: Europe Glioblastoma Multiforme Treatment Market Attractiveness Analysis by Drug Class, 2016-2032
  - Figure 47: Europe Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by End-usein 2022
  - Figure 48: Europe Glioblastoma Multiforme Treatment Market Attractiveness Analysis by End-use, 2016-2032
  - Figure 49: Europe Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 50: Europe Glioblastoma Multiforme Treatment Market Attractiveness Analysis by Country, 2016-2032
  - Figure 51: Europe Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) (2016-2032)
  - Figure 52: Europe Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 53: Europe Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Treatment (2016-2032)
  - Figure 54: Europe Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Figure 55: Europe Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
  - Figure 56: Europe Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 57: Europe Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Treatment (2016-2032)
  - Figure 58: Europe Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Figure 59: Europe Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
  - Figure 60: Europe Glioblastoma Multiforme Treatment Market Share Comparison by Country (2016-2032)
  - Figure 61: Europe Glioblastoma Multiforme Treatment Market Share Comparison by Treatment (2016-2032)
  - Figure 62: Europe Glioblastoma Multiforme Treatment Market Share Comparison by Drug Class (2016-2032)
  - Figure 63: Europe Glioblastoma Multiforme Treatment Market Share Comparison by End-use (2016-2032)
  - Figure 64: Asia-Pacific Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by Treatmentin 2022
  - Figure 65: Asia-Pacific Glioblastoma Multiforme Treatment Market Attractiveness Analysis by Treatment, 2016-2032
  - Figure 66: Asia-Pacific Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by Drug Classin 2022
  - Figure 67: Asia-Pacific Glioblastoma Multiforme Treatment Market Attractiveness Analysis by Drug Class, 2016-2032
  - Figure 68: Asia-Pacific Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by End-usein 2022
  - Figure 69: Asia-Pacific Glioblastoma Multiforme Treatment Market Attractiveness Analysis by End-use, 2016-2032
  - Figure 70: Asia-Pacific Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 71: Asia-Pacific Glioblastoma Multiforme Treatment Market Attractiveness Analysis by Country, 2016-2032
  - Figure 72: Asia-Pacific Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) (2016-2032)
  - Figure 73: Asia-Pacific Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 74: Asia-Pacific Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Treatment (2016-2032)
  - Figure 75: Asia-Pacific Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Figure 76: Asia-Pacific Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
  - Figure 77: Asia-Pacific Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 78: Asia-Pacific Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Treatment (2016-2032)
  - Figure 79: Asia-Pacific Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Figure 80: Asia-Pacific Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
  - Figure 81: Asia-Pacific Glioblastoma Multiforme Treatment Market Share Comparison by Country (2016-2032)
  - Figure 82: Asia-Pacific Glioblastoma Multiforme Treatment Market Share Comparison by Treatment (2016-2032)
  - Figure 83: Asia-Pacific Glioblastoma Multiforme Treatment Market Share Comparison by Drug Class (2016-2032)
  - Figure 84: Asia-Pacific Glioblastoma Multiforme Treatment Market Share Comparison by End-use (2016-2032)
  - Figure 85: South America Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by Treatmentin 2022
  - Figure 86: South America Glioblastoma Multiforme Treatment Market Attractiveness Analysis by Treatment, 2016-2032
  - Figure 87: South America Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by Drug Classin 2022
  - Figure 88: South America Glioblastoma Multiforme Treatment Market Attractiveness Analysis by Drug Class, 2016-2032
  - Figure 89: South America Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by End-usein 2022
  - Figure 90: South America Glioblastoma Multiforme Treatment Market Attractiveness Analysis by End-use, 2016-2032
  - Figure 91: South America Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 92: South America Glioblastoma Multiforme Treatment Market Attractiveness Analysis by Country, 2016-2032
  - Figure 93: South America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) (2016-2032)
  - Figure 94: South America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 95: South America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Treatment (2016-2032)
  - Figure 96: South America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Figure 97: South America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
  - Figure 98: South America Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 99: South America Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Treatment (2016-2032)
  - Figure 100: South America Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Figure 101: South America Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
  - Figure 102: South America Glioblastoma Multiforme Treatment Market Share Comparison by Country (2016-2032)
  - Figure 103: South America Glioblastoma Multiforme Treatment Market Share Comparison by Treatment (2016-2032)
  - Figure 104: South America Glioblastoma Multiforme Treatment Market Share Comparison by Drug Class (2016-2032)
  - Figure 105: South America Glioblastoma Multiforme Treatment Market Share Comparison by End-use (2016-2032)
  - Figure 106: Middle East and Africa Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by Treatmentin 2022
  - Figure 107: Middle East and Africa Glioblastoma Multiforme Treatment Market Attractiveness Analysis by Treatment, 2016-2032
  - Figure 108: Middle East and Africa Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by Drug Classin 2022
  - Figure 109: Middle East and Africa Glioblastoma Multiforme Treatment Market Attractiveness Analysis by Drug Class, 2016-2032
  - Figure 110: Middle East and Africa Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by End-usein 2022
  - Figure 111: Middle East and Africa Glioblastoma Multiforme Treatment Market Attractiveness Analysis by End-use, 2016-2032
  - Figure 112: Middle East and Africa Glioblastoma Multiforme Treatment Revenue (US$ Mn) Market Share by Country in 2022
  - Figure 113: Middle East and Africa Glioblastoma Multiforme Treatment Market Attractiveness Analysis by Country, 2016-2032
  - Figure 114: Middle East and Africa Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) (2016-2032)
  - Figure 115: Middle East and Africa Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Figure 116: Middle East and Africa Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Treatment (2016-2032)
  - Figure 117: Middle East and Africa Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Figure 118: Middle East and Africa Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
  - Figure 119: Middle East and Africa Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Figure 120: Middle East and Africa Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Treatment (2016-2032)
  - Figure 121: Middle East and Africa Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Figure 122: Middle East and Africa Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
  - Figure 123: Middle East and Africa Glioblastoma Multiforme Treatment Market Share Comparison by Country (2016-2032)
  - Figure 124: Middle East and Africa Glioblastoma Multiforme Treatment Market Share Comparison by Treatment (2016-2032)
  - Figure 125: Middle East and Africa Glioblastoma Multiforme Treatment Market Share Comparison by Drug Class (2016-2032)
  - Figure 126: Middle East and Africa Glioblastoma Multiforme Treatment Market Share Comparison by End-use (2016-2032)
- List of Tables
  - Table 1: Global Glioblastoma Multiforme Treatment Market Comparison by Treatment (2016-2032)
  - Table 2: Global Glioblastoma Multiforme Treatment Market Comparison by Drug Class (2016-2032)
  - Table 3: Global Glioblastoma Multiforme Treatment Market Comparison by End-use (2016-2032)
  - Table 4: Global Glioblastoma Multiforme Treatment Revenue (US$ Mn) Comparison by Region (2016-2032)
  - Table 5: Global Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) (2016-2032)
  - Table 6: Global Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Region (2016-2032)
  - Table 7: Global Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Treatment (2016-2032)
  - Table 8: Global Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Table 9: Global Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
  - Table 10: Global Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Region (2016-2032)
  - Table 11: Global Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Treatment (2016-2032)
  - Table 12: Global Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Table 13: Global Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
  - Table 14: Global Glioblastoma Multiforme Treatment Market Share Comparison by Region (2016-2032)
  - Table 15: Global Glioblastoma Multiforme Treatment Market Share Comparison by Treatment (2016-2032)
  - Table 16: Global Glioblastoma Multiforme Treatment Market Share Comparison by Drug Class (2016-2032)
  - Table 17: Global Glioblastoma Multiforme Treatment Market Share Comparison by End-use (2016-2032)
  - Table 18: North America Glioblastoma Multiforme Treatment Market Comparison by Drug Class (2016-2032)
  - Table 19: North America Glioblastoma Multiforme Treatment Market Comparison by End-use (2016-2032)
  - Table 20: North America Glioblastoma Multiforme Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 21: North America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) (2016-2032)
  - Table 22: North America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 23: North America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Treatment (2016-2032)
  - Table 24: North America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Table 25: North America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
  - Table 26: North America Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 27: North America Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Treatment (2016-2032)
  - Table 28: North America Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Table 29: North America Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
  - Table 30: North America Glioblastoma Multiforme Treatment Market Share Comparison by Country (2016-2032)
  - Table 31: North America Glioblastoma Multiforme Treatment Market Share Comparison by Treatment (2016-2032)
  - Table 32: North America Glioblastoma Multiforme Treatment Market Share Comparison by Drug Class (2016-2032)
  - Table 33: North America Glioblastoma Multiforme Treatment Market Share Comparison by End-use (2016-2032)
  - Table 34: Europe Glioblastoma Multiforme Treatment Market Comparison by Treatment (2016-2032)
  - Table 35: Europe Glioblastoma Multiforme Treatment Market Comparison by Drug Class (2016-2032)
  - Table 36: Europe Glioblastoma Multiforme Treatment Market Comparison by End-use (2016-2032)
  - Table 37: Europe Glioblastoma Multiforme Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 38: Europe Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) (2016-2032)
  - Table 39: Europe Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 40: Europe Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Treatment (2016-2032)
  - Table 41: Europe Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Table 42: Europe Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
  - Table 43: Europe Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 44: Europe Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Treatment (2016-2032)
  - Table 45: Europe Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Table 46: Europe Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
  - Table 47: Europe Glioblastoma Multiforme Treatment Market Share Comparison by Country (2016-2032)
  - Table 48: Europe Glioblastoma Multiforme Treatment Market Share Comparison by Treatment (2016-2032)
  - Table 49: Europe Glioblastoma Multiforme Treatment Market Share Comparison by Drug Class (2016-2032)
  - Table 50: Europe Glioblastoma Multiforme Treatment Market Share Comparison by End-use (2016-2032)
  - Table 51: Asia-Pacific Glioblastoma Multiforme Treatment Market Comparison by Treatment (2016-2032)
  - Table 52: Asia-Pacific Glioblastoma Multiforme Treatment Market Comparison by Drug Class (2016-2032)
  - Table 53: Asia-Pacific Glioblastoma Multiforme Treatment Market Comparison by End-use (2016-2032)
  - Table 54: Asia-Pacific Glioblastoma Multiforme Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 55: Asia-Pacific Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) (2016-2032)
  - Table 56: Asia-Pacific Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 57: Asia-Pacific Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Treatment (2016-2032)
  - Table 58: Asia-Pacific Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Table 59: Asia-Pacific Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
  - Table 60: Asia-Pacific Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 61: Asia-Pacific Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Treatment (2016-2032)
  - Table 62: Asia-Pacific Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Table 63: Asia-Pacific Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
  - Table 64: Asia-Pacific Glioblastoma Multiforme Treatment Market Share Comparison by Country (2016-2032)
  - Table 65: Asia-Pacific Glioblastoma Multiforme Treatment Market Share Comparison by Treatment (2016-2032)
  - Table 66: Asia-Pacific Glioblastoma Multiforme Treatment Market Share Comparison by Drug Class (2016-2032)
  - Table 67: Asia-Pacific Glioblastoma Multiforme Treatment Market Share Comparison by End-use (2016-2032)
  - Table 68: South America Glioblastoma Multiforme Treatment Market Comparison by Treatment (2016-2032)
  - Table 69: South America Glioblastoma Multiforme Treatment Market Comparison by Drug Class (2016-2032)
  - Table 70: South America Glioblastoma Multiforme Treatment Market Comparison by End-use (2016-2032)
  - Table 71: South America Glioblastoma Multiforme Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 72: South America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) (2016-2032)
  - Table 73: South America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 74: South America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Treatment (2016-2032)
  - Table 75: South America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Table 76: South America Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
  - Table 77: South America Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 78: South America Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Treatment (2016-2032)
  - Table 79: South America Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Table 80: South America Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
  - Table 81: South America Glioblastoma Multiforme Treatment Market Share Comparison by Country (2016-2032)
  - Table 82: South America Glioblastoma Multiforme Treatment Market Share Comparison by Treatment (2016-2032)
  - Table 83: South America Glioblastoma Multiforme Treatment Market Share Comparison by Drug Class (2016-2032)
  - Table 84: South America Glioblastoma Multiforme Treatment Market Share Comparison by End-use (2016-2032)
  - Table 85: Middle East and Africa Glioblastoma Multiforme Treatment Market Comparison by Treatment (2016-2032)
  - Table 86: Middle East and Africa Glioblastoma Multiforme Treatment Market Comparison by Drug Class (2016-2032)
  - Table 87: Middle East and Africa Glioblastoma Multiforme Treatment Market Comparison by End-use (2016-2032)
  - Table 88: Middle East and Africa Glioblastoma Multiforme Treatment Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 89: Middle East and Africa Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) (2016-2032)
  - Table 90: Middle East and Africa Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Country (2016-2032)
  - Table 91: Middle East and Africa Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Treatment (2016-2032)
  - Table 92: Middle East and Africa Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by Drug Class (2016-2032)
  - Table 93: Middle East and Africa Glioblastoma Multiforme Treatment Market Revenue (US$ Mn) Comparison by End-use (2016-2032)
  - Table 94: Middle East and Africa Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Country (2016-2032)
  - Table 95: Middle East and Africa Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Treatment (2016-2032)
  - Table 96: Middle East and Africa Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by Drug Class (2016-2032)
  - Table 97: Middle East and Africa Glioblastoma Multiforme Treatment Market Y-o-Y Growth Rate Comparison by End-use (2016-2032)
  - Table 98: Middle East and Africa Glioblastoma Multiforme Treatment Market Share Comparison by Country (2016-2032)
  - Table 99: Middle East and Africa Glioblastoma Multiforme Treatment Market Share Comparison by Treatment (2016-2032)
  - Table 100: Middle East and Africa Glioblastoma Multiforme Treatment Market Share Comparison by Drug Class (2016-2032)
  - Table 101: Middle East and Africa Glioblastoma Multiforme Treatment Market Share Comparison by End-use (2016-2032)
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- Merck & Co.Inc.
- Amneal Pharmaceuticals
- Arbor Pharmaceuticals LLC
- Pfizer Inc.
- Amgen Inc.
- Boston Biomedical Inc.
- Sun Pharmaceutical Industries Ltd.
- Karyopharm Therapeutics Inc.
- Other Key Players